• CFTRinh-172 in CFTR Inhibitor Workflows: Protocols & Insight

  2026-06-03

  CFTRinh-172 empowers precise dissection of CFTR chloride channel function in diverse epithelial models. This article delivers advanced, evidence-driven protocols and troubleshooting strategies for cystic fibrosis and secretory diarrhea research, translating recent SHC-1/MAPK pathway discoveries into actionable laboratory practices.

• ORAI2 Drives Early Postirradiation Salivary Gland Fibrosis v

  2026-06-03

  This study identifies ORAI2-mediated calcium signaling as a pivotal driver of early-stage fibrosis in irradiated salivary glands. By mapping a novel ORAI2/JNK/NFAT1/TGF-β1 axis, the research highlights new molecular targets for mitigating radiation-induced hyposalivation and tissue fibrosis.

• CFTRinh-172 in Epithelial Biology: Selectivity, Models, and

  2026-06-02

  Explore how CFTRinh-172, a potent CFTR inhibitor, advances epithelial research through its selectivity and unique mechanistic properties. This article provides deep insight into model system considerations and assay optimization, offering practical guidance beyond conventional overviews.

• Multidrug Resistance Dynamics in CREC: Insights from Guangdo

  2026-06-02

  This study provides a comprehensive molecular epidemiology of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong, China. The findings reveal high prevalence and transmissibility of resistance determinants, particularly the blaNDM-1 gene, with significant clinical implications for infection control and resistance monitoring.

• THZ1 (SKU A8882): Precision CDK7 Inhibition for Reliable Can

  2026-06-01

  This article delivers scenario-driven guidance for biomedical researchers using THZ1 (SKU A8882), a covalent CDK7 inhibitor, in cell viability and transcription regulation assays. Drawing on peer-reviewed data and workflow challenges, it demonstrates how THZ1 ensures reproducibility and sensitivity in T-ALL and broader cancer biology research.

• ZCL278: Selective Cdc42 Inhibitor Empowering Cell Motility R

  2026-06-01

  ZCL278 delivers precision Cdc42 inhibition for cell motility, neuronal branching, and fibrotic signaling studies. Its workflow adaptability and rapid, selective action help researchers unravel complex signaling networks and optimize cellular assays with confidence.

• RAB31 Defines an ESCRT-Independent Exosome Biogenesis Pathwa

  2026-05-31

  The study by Wei et al. identifies RAB31 as a pivotal regulator marking and controlling an ESCRT-independent pathway for exosome biogenesis. Through mechanistic dissection, the research reveals how RAB31 coordinates intraluminal vesicle formation and prevents MVE degradation—offering new molecular insight and experimental strategies for exosome research.

• Polymyxin B Sulfate: Mechanistic Clarity and Translational I

  2026-05-30

  Explore how Polymyxin B (sulfate) is reshaping infection and immunity research. This article bridges mechanistic insight with actionable strategy, guiding translational scientists through the antibiotic's dual bactericidal and immunomodulatory roles, its relevance amid rising multidrug resistance, and protocol best practices for robust experimental design.

• Mapping Mutational Drivers in Multiple Myeloma Cell Lines

  2026-05-29

  This study delivers the first comprehensive exome-wide analysis of human multiple myeloma cell lines, revealing both known and novel mutational drivers implicated in tumor progression and drug resistance. The findings equip researchers with a molecular atlas to refine experimental model selection and inform the development of targeted therapies for hematological malignancies.

• MMP7 Drives EMT and Fibrosis via E-cadherin/β-Catenin in BA

  2026-05-29

  This study uncovers how matrix metalloproteinase 7 (MMP7) promotes liver fibrosis in biliary atresia by inducing epithelial–mesenchymal transition (EMT) through E-cadherin cleavage and β-catenin pathway activation. The findings identify MMP7 as a mechanistic link and potential therapeutic target in pediatric liver fibrogenesis.

• Practical Use of Angiotensin I/II (1-5) in RAS Research

  2026-05-28

  Angiotensin I/II (1-5) (Asp-Arg-Val-Tyr-Ile) enables precise modeling of the renin-angiotensin system in cardiovascular and renal workflows, particularly for blood pressure and aldosterone regulation studies. This peptide is not suitable for non-RAS or unrelated signaling research due to its specific biochemical properties and solubility constraints.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui

  2026-05-28

  DiI (DiIC18(3)) is a lipophilic orange fluorescent probe designed for high-contrast labeling of plasma membranes in live and fixed cells. It addresses the need for robust membrane visualization in workflows including neuronal tracing, cell migration assays, and lipoprotein labeling. This probe is not suitable for protocols requiring water solubility or intracellular organelle labeling.

• Hyperthermia and Cisplatin Synergize via Caspase-8 for Tumor

  2026-05-27

  This study reveals that combining hyperthermia with cisplatin therapy enhances caspase-8 accumulation and activation, promoting both apoptosis and pyroptosis in cancer cells. The findings highlight a distinct caspase signaling mechanism with implications for optimizing apoptosis assays and targeted cancer therapies.

• Lisinopril Dihydrate in Hypertension and Cardiorenal Researc

  2026-05-27

  Lisinopril dihydrate, a precision ACE inhibitor, offers unmatched selectivity and reproducibility for modeling hypertension, heart failure, and diabetic nephropathy. Explore optimized workflows, troubleshooting strategies, and the translational impact of evidence-backed protocol enhancements.

• Carfilzomib (PR-171): Precision Proteasome Inhibition in Can

  2026-05-26

  Carfilzomib (PR-171) is a highly potent, irreversible proteasome inhibitor used in cancer research to induce apoptosis and disrupt protein degradation. Its selectivity for the chymotrypsin-like site of the 20S proteasome underpins its efficacy in preclinical tumor models. This article provides a structured review of its mechanism, benchmark data, and integration into translational workflows.

16881 records 1/1126 page Next 12345 下5页 Last page